TIRZEPATIDE VERSUS SEMAGLUTIDE: A COMPREHENSIVE REVIEW OF COMPARATIVE EFFICACY, SAFETY, AND METABOLIC OUTCOMES IN TYPE 2 DIABETES AND OBESITY

Type 2 diabetes (T2D) and obesity represent chronic, escalating global health crises that necessitate potent pharmacological strategies. This comprehensive review compares the relative efficacy, safety, and overall metabolic benefits of tirzepatide (TZP), a novel dual GIP/GLP-1 receptor agonist, against semaglutide (SEMA), a selective GLP-1 receptor agonist. A systematic review was conducted, synthesizing data from 36 eligible Randomized Controlled Trials (RCTs), Indirect Treatment Comparisons (ITCs), and Real-World Evidence (RWE) studies involving adults with T2D and/or overweight/obesity. Key outcomes assessed included changes in HbA1c, body weight, and gastrointestinal adverse events (AEs). Findings from head-to-head RCTs (e.g., SURPASS-2) definitively demonstrated that all tested doses of once-weekly TZP (5 mg, 10 mg, and 15 mg) achieved statistically significantly greater reductions in both HbA1c and body weight compared to SEMA 1.0 mg. Furthermore, TZP significantly increased the proportion of participants achieving challenging composite endpoints, such as reaching stringent glycemic targets combined with substantial weight loss (e.g., ≥10%), without clinically significant hypoglycemia. ITCs comparing maximal doses also suggested that TZP 15 mg conferred superior efficacy for both weight and glycemic control over SEMA 2.4 mg in patients with T2D/obesity. The safety profile of TZP was generally consistent with the incretin class, characterized predominantly by transient gastrointestinal AEs (nausea, diarrhea, vomiting). In conclusion, tirzepatide, leveraging its dual GIP/GLP-1 agonism, provides consistently superior efficacy for glycemic control and body weight reduction compared to semaglutide, positioning dual incretin agonism as a powerful advance in treating T2D and obesity.